The Alphabet, Astellas, Novartis and WuXi AppTec-backed T-cell cancer therapy developer has filed to list on the Nasdaq Global Market.
TScan Therapeutics, a US-based T-cell immunotherapy developer backed by internet and technology group Alphabet and pharmaceutical firms Astellas, Novartis and WuXi AppTec, has filed for an initial public offering (IPO). The company has set a placeholder figure of $100m and intends to float on the Nasdaq Global Market. Morgan Stanley, Jefferies, Cowen and Barclays Capital…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.